PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28117385-7 2017 RESULTS: Of 265 PREVAIL patients with radiographic progression and evaluable PSA levels on the enzalutamide arm, nearly one-quarter had a nonrising PSA. enzalutamide 95-107 aminopeptidase puromycin sensitive Homo sapiens 77-80 28614217-0 2017 PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. enzalutamide 104-116 aminopeptidase puromycin sensitive Homo sapiens 0-3 28614217-1 2017 RATIONALE: PSA responses have been associated with a survival benefit in patients treated with enzalutamide in retrospective analyses. enzalutamide 95-107 aminopeptidase puromycin sensitive Homo sapiens 11-14 28614217-2 2017 PATIENT CONCERNS: However the prognostic value of PSA declines in highly pretreated patients receiving enzalutamide remains to be defined. enzalutamide 103-115 aminopeptidase puromycin sensitive Homo sapiens 50-53 28614217-9 2017 LESSONS: Our study supports the prognostic value of PSA declines in heavily treated patients receiving enzalutamide. enzalutamide 103-115 aminopeptidase puromycin sensitive Homo sapiens 52-55 28117385-10 2017 CONCLUSIONS: Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with enzalutamide. enzalutamide 110-122 aminopeptidase puromycin sensitive Homo sapiens 24-27 28117385-11 2017 As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. enzalutamide 146-158 aminopeptidase puromycin sensitive Homo sapiens 82-85 25131864-8 2014 Enzalutamide was associated with significant benefits over the placebo considering time-to-event outcomes(i.e. prolonged overall survival[OS], delayed time to prostatic specific antigen[PSA]progression[TTPP], prolonged radiographic progression free survival[rPFS], time to the first skeletal related event[SRE])as well as objective response outcomes(i.e. PSA, soft tissue, and quality of life[QOL]). enzalutamide 0-12 aminopeptidase puromycin sensitive Homo sapiens 186-189 25131864-8 2014 Enzalutamide was associated with significant benefits over the placebo considering time-to-event outcomes(i.e. prolonged overall survival[OS], delayed time to prostatic specific antigen[PSA]progression[TTPP], prolonged radiographic progression free survival[rPFS], time to the first skeletal related event[SRE])as well as objective response outcomes(i.e. PSA, soft tissue, and quality of life[QOL]). enzalutamide 0-12 aminopeptidase puromycin sensitive Homo sapiens 355-358 34885192-3 2021 PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). enzalutamide 146-158 aminopeptidase puromycin sensitive Homo sapiens 200-203 34885192-8 2021 PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone. enzalutamide 68-80 aminopeptidase puromycin sensitive Homo sapiens 0-3 34385241-0 2021 A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. enzalutamide 30-42 aminopeptidase puromycin sensitive Homo sapiens 162-165 34385241-0 2021 A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. enzalutamide 63-75 aminopeptidase puromycin sensitive Homo sapiens 162-165 34385241-5 2021 The main objective of EMBARK is the comparative assessment of enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa to improve metastasis-free survival (MFS) in patients with high-risk nmCSPC PSA recurrence after definitive therapy. enzalutamide 62-74 aminopeptidase puromycin sensitive Homo sapiens 276-279 34385241-5 2021 The main objective of EMBARK is the comparative assessment of enzalutamide plus leuprolide (luteinising hormone-releasing hormone agonist (LHRHa)) or enzalutamide monotherapy versus monotherapy LHRHa to improve metastasis-free survival (MFS) in patients with high-risk nmCSPC PSA recurrence after definitive therapy. enzalutamide 150-162 aminopeptidase puromycin sensitive Homo sapiens 276-279